Yahoo! Finance Search - Finance Home - Yahoo! - Help

Saturday, January 21 2017 9:28am ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Major News
Latest News
Saturday, Jan 21, 2017
·[$$] Payout Appeal
at Barrons.com - 1 hour, 27 minutes ago
·Novartis’s 4Q16 Earnings: What Is Expected?
- Fri 5:41 pm ET
·The Biggest Loser: Bristol-Myers Sinks 11%
at Barrons.com - Fri 5:09 pm ET
·[$$] Merck Settles With Bristol-Meyers, Ono Over Cancer-Drug Patent
at The Wall Street Journal Online - Fri 4:55 pm ET
·Jim Cramer on Bristol-Myers' Opdivo/Yervoy Combo: 'That Story Was Taken Away From Us'
at TheStreet.com - Fri 4:29 pm ET
·Merck, Bristol-Myers agree to settle Keytruda patent suit
Reuters - Fri 4:23 pm ET
·Merck will pay $625 million and royalties to settle Keytruda patent litigation with Bristol-Myers Squibb and Ono Pharma
at MarketWatch - Fri 4:16 pm ET
·Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation
Business Wire - Fri 4:01 pm ET
·Merck Announces Settlement and License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation
Business Wire - Fri 4:01 pm ET
Friday, Jan 20, 2017
·Bristol-Myers Squibb: There Goes Any Chance for Upside
at Barrons.com - Fri 12:14 pm ET
·Bristol-Myers’ tight-lipped pass on accelerated lung cancer drug approval leaves field wide open for Merck
at MarketWatch - Fri 11:11 am ET
·[$$] Bristol-Myers shares slide on immunotherapy setback
at FT.com - Fri 10:17 am ET
·Heron Therapeutics Launches $150M Public Offering
at Investopedia - Fri 8:47 am ET
·Johnson & Johnson's Ethicon Endo-Surgery to acquire medical device maker Megadyne Medical Products
at MarketWatch - Fri 8:39 am ET
·Ethicon Announces Acquisition of Megadyne Medical Products, Inc.
PR Newswire - Fri 8:30 am ET
·Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly
at TheStreet.com - Fri 8:17 am ET
·Blog Coverage AbbVie Received FDA Approval for Treatment for Marginal Zone Lymphoma
- Fri 8:15 am ET
·Bristol-Myers Squibb stock sinks 7.2% after it says it won't pursue accelerated approval for lung cancer combination treatment
at MarketWatch - Fri 7:48 am ET
·Why Johnson & Johnson’s 4Q16 Revenues Could Grow
- Fri 7:38 am ET
·[$$] AbbVie Hikes the Price of Humira: Stock May Jump
at Barrons.com - Fri 7:38 am ET
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Major Headlines
More Finance RSS Feeds


Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?